CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.
ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.
Insurance Australia Group pre-released guidance and announced its expectations for FY21E cash earnings of A$747mn and guided to low single-digit growth in FY22E.
IAG trades on a forward dividend yield of 3.8%.
Buy IAG with a stop loss @ $4.70
6/8 Update: IAG now trading $5.00
9/8 Update: IAG is trading $5.20 after Suncorp released strong earnings today.
REA Group is under Aglo Engine buy conditions and among the best-performing stocks in our ASX model portfolio. REA was added to the ASX 100 model in September last year at $107.80 and is up 48.40%, (including dividends), to $159.42.
FY21 Revenue increased 13% to $927m and EBITDA increased 19% to $564m. Net Profit After Tax (NPAT) saw a similar lift of 18% to $318m.
The div increases to $0.72 per share and the ex-dividend date is 26 August.
We recommend buying the dip in REA, so please watch for the next Algo Engine buy signal. Long-term earnings growth will be underpinned by the recent acquisition of mortgage broker, Mortgage Choice.
Send our ASX Research to your Inbox
Or start a free thirty day trial for our full service, which includes our ASX Research.